Assess whether the carve-out is operable on day one (0182f8)

SITUATION Regulatory-approval critical-path calendar arrived with a founder who will not sign a non-compete for commercial-diligence partner. That is a M&A Due Diligence Legal, IP, and Regulatory decision on the carve-out is operable in a cross-border deal with earnout-heavy structure.

DECISION Commercial-diligence partner in a cross-border deal with earnout-heavy structure must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after a founder who will not sign a non-compete.

HYPOTHESES TO TEST 1. Regulatory-approval critical-path calendar reads as Proceed once a founder who will not sign a non-compete is lined up to the same M&A Due Diligence population. 2. Regulatory-approval critical-path calendar is closer to Reprice after a founder who will not sign a non-compete; Proceed would over-claim this Legal, IP, and Regulatory extract. 3. Walk is still live in regulatory-approval critical-path calendar for commercial-diligence partner in a cross-border deal with earnout-heavy structure. 4. Regulatory-approval critical-path calendar is missing the fact commercial-diligence partner needs after a founder who will not sign a non-compete; stop this M&A Due Diligence close.

ANALYSIS REQUIRED 1. Tie quality-of-earnings, working-capital, and contingent items in regulatory-approval critical-path calendar to the carve-out is operable. 2. Name the document commercial-diligence partner still needs before signing. 3. Test whether a founder who will not sign a non-compete is a diligence gap, a price chip, or a walk-away. 4. For this M&A Due Diligence Legal, IP, and Regulatory file, read regulatory-approval critical-path calendar against a founder who will not sign a non-compete and write the one fact that would move the carve-out is operable for commercial-diligence partner.

RECOMMENDATION Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Legal, IP, and Regulatory packet (regulatory-approval critical-path calendar after a founder who will not sign a non-compete). The follow-on Legal, IP, and Regulatory action is what commercial-diligence partner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on the carve-out is operable, then the evidence in regulatory-approval critical-path calendar, then the action for commercial-diligence partner - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - What changes the carve-out is operable if a founder who will not sign a non-compete is later withdrawn - Named option among Proceed, Reprice, Walk and the fact that kills the others